HL7 v2.3.1 Vocabulary
0.1.0 - ci-build

HL7 v2.3.1 Vocabulary, published by HL7/FO. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/frankoemig/hl7.v2.terminology.v231/ and changes regularly. See the Directory of published versions

## CodeSystem: Vaccines Administered (2.3.1 - 1.1.0) (Experimental)

Official URL: http://terminology.hl7.org/v2plusvocab/CodeSystem/vaccinesAdministeredHL7 | Version: 1.1.0
Active as of 2026-01-27 | Computable Name: VaccinesAdministeredHL7
Other Identifiers: OID:2.16.840.1.113883.18.182
Copyright/Legal: HL7 Inc., 2026

Code system of codes specifying the administered vaccines, and used only in HL7 releases 2.3, 2.3.1, and 2.4 of the standard. This code system was superceded when the US Centers of Disease Control began publishing the codes directly; the code system to be used now is 2.16.840.1.113883.12.292 PH_VaccinesAdministeredCVX_CDC_NIP.

This Code system is referenced in the content logical definition of the following value sets:

- Hl7VSvaccinesAdministered

Properties

This code system defines the following properties for its concepts

Name | Code | URI | Type | Description
versionIntroduced | versionIntroduced | http://terminology.hl7.org/v2plusvocab/CodeSystem/Property#versionIntroduced | string | version when was this code introduced
versionDeprecated | versionDeprecated | http://terminology.hl7.org/v2plusvocab/CodeSystem/Property#versionDeprecated | string | version when was this code deprecated
status | status | http://hl7.org/fhir/concept-properties#status | code | A code that indicates the status of the concept. Typical values are active, experimental, deprecated, and retired
comment | comment | http://terminology.hl7.org/v2plusvocab/CodeSystem/Property#comment | string | A string that provides additional detail pertinent to the use or understanding of the concept
usage | usage | http://terminology.hl7.org/v2plusvocab/CodeSystem/Property#usage | string | usage notes for this code
modified | modified | http://terminology.hl7.org/v2plusvocab/CodeSystem/Property#modified | dateTime | date of last modification

Concepts

This case-sensitive code system `http://terminology.hl7.org/v2plusvocab/CodeSystem/vaccinesAdministeredHL7` defines the following codes:

Code | Display | Definition | versionIntroduced
01 | DTP | DTP | 2.3
02 | OPV | OPV | 2.3
03 | MMR | MMR | 2.3
04 | M/R | M/R | 2.3
05 | Measles | Measles | 2.3
06 | Rubella | Rubella | 2.3
07 | Mumps | Mumps | 2.3
08 | Hep B, adolescent or pediatric | Hep B, adolescent or pediatric | 2.3
09 | Td (Adult) | Td (Adult) | 2.3
10 | IPV | IPV | 2.3
11 | Pertussis | Pertussis | 2.3
12 | Diphtheria antitoxin | Diphtheria antitoxin | 2.3
13 | TIG | TIG | 2.3
14 | IG, NOS | IG, NOS | 2.3
15 | Influenza—split (incl. purified surface antigen) | Influenza—split (incl. purified surface antigen) | 2.3
16 | Influenza—whole | Influenza—whole | 2.3
17 | Hib, NOS | Hib, NOS | 2.3
18 | Rabies, intramuscular injection | Rabies, intramuscular injection | 2.3
19 | BCG | BCG | 2.3
20 | DTaP | DTaP | 2.3
21 | Varicella | Varicella | 2.3
22 | DTP-Hib | DTP-Hib | 2.3
23 | Plague | Plague | 2.3
24 | Anthrax | Anthrax | 2.3
25 | Typhoid—oral | Typhoid—oral | 2.3
26 | Cholera | Cholera | 2.3
27 | Botulinum antitoxin | Botulinum antitoxin | 2.3
28 | DT(pediatric) | DT(pediatric) | 2.3
29 | CMVIG | CMVIG | 2.3
30 | HBIG | HBIG | 2.3
31 | Hep A, pediatric, NOS | Hep A, pediatric, NOS | 2.3
32 | Meningococcal | Meningococcal | 2.3
33 | Pneumococcal | Pneumococcal | 2.3
34 | RIG | RIG | 2.3
35 | Tetanus toxoid | Tetanus toxoid | 2.3
36 | VZIG | VZIG | 2.3
37 | Yellow fever | Yellow fever | 2.3
38 | Rubella/Mumps | Rubella/Mumps | 2.3
39 | Japanese encephalitis | Japanese encephalitis | 2.3
40 | Rabies, intradermal injection | Rabies, intradermal injection | 2.3
41 | Typhoid-parenteral | Typhoid-parenteral | 2.3
42 | Hep B, adolescent/high risk infant | Hep B, adolescent/high risk infant | 2.3
43 | Hep B, adult | Hep B, adult | 2.3
44 | Hep B, dialysis | Hep B, dialysis | 2.3
45 | Hep B, NOS | Hep B, NOS | 2.3
46 | Hib (PRP-D) | Hib (PRP-D) | 2.3
47 | Hib (HbOC) | Hib (HbOC) | 2.3
48 | Hib (PRP-T) | Hib (PRP-T) | 2.3
49 | Hib (PRP-OMP) | Hib (PRP-OMP) | 2.3
50 | DtaP-Hib | DtaP-Hib | 2.3
51 | Hib-Hep B | Hib-Hep B | 2.3
52 | Hep A - adult | Hep A - adult | 2.3
53 | Typhoid, parenteral, AKD (U.S. military) | Typhoid, parenteral, AKD (U.S. military) | 2.3.1
54 | Adenovirus, type 4 | Adenovirus, type 4 | 2.3.1
55 | Adenovirus, type 7 | Adenovirus, type 7 | 2.3.1
56 | Dengue fever | Dengue fever | 2.3.1
57 | Hantavirus | Hantavirus | 2.3.1
58 | Hep C | Hep C | 2.3.1
59 | Hep E | Hep E | 2.3.1
60 | Herpes simplex 2 | Herpes simplex 2 | 2.3.1
61 | HIV | HIV | 2.3.1
62 | HPV | HPV | 2.3.1
63 | Junin virus | Junin virus | 2.3.1
64 | Leishmaniasis | Leishmaniasis | 2.3.1
65 | Leprosy | Leprosy | 2.3.1
66 | Lyme disease | Lyme disease | 2.3.1
67 | malaria | malaria | 2.3.1
68 | Melanoma | Melanoma | 2.3.1
69 | Parainfluenza-3 | Parainfluenza-3 | 2.3.1
70 | Q fever | Q fever | 2.3.1
71 | RSV-IGIV | RSV-IGIV | 2.3.1
72 | Rheumatic fever | Rheumatic fever | 2.3.1
73 | Rift Valley fever | Rift Valley fever | 2.3.1
74 | Rotavirus | Rotavirus | 2.3.1
75 | Smallpox | Smallpox | 2.3.1
76 | Staphylococcus bacterio lysate | Staphylococcus bacterio lysate | 2.3.1
77 | Tick-borne encephalitis | Tick-borne encephalitis | 2.3.1
78 | Tularemia vaccine | Tularemia vaccine | 2.3.1
79 | Vaccinia immune globulin | Vaccinia immune globulin | 2.3.1
80 | VEE, live | VEE, live | 2.3.1
81 | VEE, inactivated | VEE, inactivated | 2.3.1
82 | Adenovirus, NOS | Adenovirus, NOS | 2.3.1
83 | Hep A, ped/adol, 2 dose | Hep A, ped/adol, 2 dose | 2.3.1
84 | Hep A, ped/adol, 3 dose | Hep A, ped/adol, 3 dose | 2.3.1
85 | Hep A, NOS | Hep A, NOS | 2.3.1
86 | IG | IG | 2.3.1
87 | IGIV | IGIV | 2.3.1
88 | Influenza, NOS | Influenza, NOS | 2.3.1
89 | polio, NOS | Polio, NOS | 2.3.1
90 | Rabies, NOS | Rabies, NOS | 2.3.1
91 | typhoid, NOS | Typhoid, NOS | 2.3.1
92 | VEE, NOS | VEE, NOS | 2.3.1